R&D Solutions segment profit is IQVIA's reportable-segment profit for its outsourced clinical-research and related R&D services business.
IQVIA reported $526M of R&D Solutions segment profit in Q2 2026, up 11.2% from $473M a year earlier.
Profit conversion matters more than revenue alone
The segment's revenue grew 8.8%, so segment profit grew faster in the quarter. That can indicate favorable operating leverage, but the measure still inherits IQVIA's segment accounting and excludes corporate and unallocated items.
The R&D Solutions segment profit margin makes that conversion easier to compare across periods.
Primary sources: IQVIA Q2 2026 Form 10-Q and Q2 2026 earnings release filed with the SEC.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare R&D segment profit growth with revenue growth before corporate and unallocated costs.
Explore more topics in the Financial Research Encyclopedia.